Biotechnology · Healthcare
CFO, Chief Accounting Officer
2023-09-11–present
Chief Accounting Officer
4D Molecular Therapeutics, Inc. (FDMT)Equibles does not estimate personal net worth.
Get an email with a short summary when 4D Molecular Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FDMT alertsUneek Mehra is recorded as CFO and Chief Accounting Officer at 4D Molecular Therapeutics, Inc. (FDMT) since September 11, 2023. 4D Molecular Therapeutics, Inc. reported in an 8-K filed July 2, 2025 that Uneek Mehra resigned as Chief Financial and Business Officer, effective July 15, 2025. The same filing states: “Mr. Mehra’s departure is not the result of any disagreement regarding the Company’s operations, financial statements, guidance, corporate outlook, internal controls, auditors, policies or practices.” 4D Molecular Therapeutics, Inc. reported in an 8-K filed September 13, 2023 that Uneek Mehra was appointed Chief Financial and Business Officer, Principal Financial Officer, Principal Accounting Officer, and Assistant Secretary, effective September 11, 2023. The proxy statement of 4D Molecular Therapeutics, Inc. reports total compensation of $823,899 for Uneek Mehra in fiscal 2024, including a base salary of $545,752. 4D Molecular Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at 4D Molecular Therapeutics, Inc. includes David Kirn (CEO and Board Member), David Kirn, M.D. (CEO), Ashoo Gupta (CFO) and 7 others.
“On June 27, 2025, Uneek Mehra informed 4D Molecular Therapeutics, Inc. (the "Company") of his intent to resign as Chief Financial and Business Officer of the Company effective as of July 15, 2025 in order to pursue other opportunities.”
“Mr. Mehra’s departure is not the result of any disagreement regarding the Company’s operations, financial statements, guidance, corporate outlook, internal controls, auditors, policies or practices.”
“On September 12, 2023, the Company announced that Uneek Mehra had joined the Company as Chief Financial and Business Officer, Principal Financial Officer, Principal Accounting Officer, and Assistant Secretary of the Company.”
2023-09-11–present
2023-09-11–present
2023-09-11–2025-07-15
Proxy statement
Start not stated–2025-04-29
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CFO, Chief Accounting Officer
2023-09-11–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | 4D Molecular Therapeutics, Inc. (FDMT) | Chief Financial and Business Officer | $545,752 | $823,899 |
“Mr. Mehra’s departure is not the result of any disagreement regarding the Company’s operations, financial statements, guidance, corporate outlook, internal controls, auditors, policies or practices.”
4D Molecular Therapeutics, Inc. (FDMT)